VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025. The Russell 3000 ...

文章核心观点 公司宣布任命Darren Cline为首席商务官及高级管理团队成员 其经验将助力阿泽图卡尔纳（azetukalner）及公司神经科学项目商业化[1][2] 公司动态 - 公司任命Darren Cline为首席商务官及高级管理团队成员 他将负责公司产品组合商业战略和运营 初期聚焦阿泽图卡尔纳及癫痫领域首次潜在上市[1] - 公司薪酬委员会授予Darren Cline购买185,800股普通股的期权 行使价为每股31.49美元 股份在四年内归属 还授予6,200个绩效股份单位 基于约三年绩效期内预定里程碑目标归属[4] 产品情况 - 阿泽图卡尔纳正处于治疗癫痫和重度抑郁症的3期试验 今年将启动双相抑郁症3期试验 预计2026年初有3期数据 为监管提交和首次商业发布铺路[1][2] - 2b期X - TOLE和开放标签扩展数据支持阿泽图卡尔纳作为重要新机制和药物的潜力 公司接近完成X - TOLE2入组 并为其潜在获批做商业准备 未来还有治疗重度抑郁症和双相抑郁症的前景[3] 新官履历 - Darren Cline有超30年生物制药行业商业和上市战略等经验 最近担任Epygenix Therapeutics总裁兼首席执行官 此前在GW Pharmaceuticals等公司任职 成功推动产品商业化[2] 公司介绍 - 公司是专注神经科学的生物制药公司 致力于发现、开发和提供改变生活的疗法 推进离子通道产品组合以满足癫痫和抑郁症等未满足医疗需求[5][6]

VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025. Fireside Chat Presentation Details: Date:Tuesday, June 10, 2025 Time:3:20-3:55 PM Eas ...

VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025. Fireside Chat Presentation Details: Date: Wednesday, May 21, 2025 Time: 10:30-10:55 AM ...

Xenon Pharmaceuticals (XENE) reported a loss of 83 cents per share for the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 94 cents. The company had incurred a loss of 62 cents per share in the year-ago quarter.The company generated revenues of $7.5 million in the first quarter, which marginally missed the Zacks Consensus Estimate of $8 million. In the year-ago quarter, Xenon did not generate any revenues. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar ...

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA – Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 – IND filing and Phase 1 study start for XEN1701, lead Nav1.7 candidate, anticipated in ...

VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. Conference Call/Webcast Information:  Date:Monday, May 12, 2025  Time:4:30 p ...

文章核心观点 公司宣布向四名新非管理人员授予股权奖励，包括78,600份股票期权和1,800份绩效股票单位 [1] 股权奖励授予情况 - 授予对象为四名新非管理人员 [1] - 授予内容包括78,600份股票期权和1,800份绩效股票单位 [1] - 授予经公司董事会薪酬委员会批准，生效日期为2025年5月2日，依据纳斯达克上市规则5635(c)(4)作为员工入职诱因授予 [1] 股票期权情况 - 行使价格为每股38.28美元，与2025年5月2日授予日公司普通股收盘价相同 [2] - 分四年归属，员工入职一周年时归属25%，之后每月最后一天归属剩余期权的1/36，需员工持续为公司服务 [2] - 每份期权有效期10年，受股票期权协议和公司2025年诱因股权奖励计划条款约束 [2] 绩效股票单位情况 - 基于约三年绩效期内达成预定里程碑目标归属（若有），需员工持续为公司服务 [2] - 每份授予受绩效股票单位奖励协议和公司2025年诱因股权奖励计划条款约束 [2] 公司简介 - 是专注神经科学的生物制药公司，致力于发现、开发和提供改变生活的疗法 [3] - 推进离子通道产品组合，以满足癫痫和抑郁症等未满足的医疗需求 [3] - 新型、高效、选择性Kv7钾通道开放剂Azetukalner是针对多种适应症处于后期临床开发的最先进、经临床验证的钾通道调节剂 [3] 联系方式 - 投资者联系：副总裁Chad Fugere，电话(857) 675-7275，邮箱investors@xenon-pharma.com [5] - 媒体联系：高级副总裁Colleen Alabiso，电话(617) 671-9238，邮箱media@xenon-pharma.com [5]

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Caroline Poacher - JPMorgan Brian Skorney - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Laura Chico - Wedbush Securities Joseph Thome - ...